A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

NCT06885424 · tracked via the Priya Life Science USA tracker

Sponsor

A2 Biotherapeutics Inc.

Phase

Observational

Started

2025-07-31

Last updated

2026-05-20

Condition(s) studied

Solid Tumor CancerSolid Tumor, Unspecified, AdultColorectal CarcinomaColorectal Carcinoma (CRC)Non Small Cell Lung CancerSmall Cell Lung Cancer ( SCLC )Pancreatic CancerNSCLCMesotheliomaOvarian CancerOvarian CarcinomaHead and Neck (HNSCC)Head and Neck CancerRenal Cell Carcinoma (Kidney Cancer)Triple Negative Breast Cancer (TNBC)

Investigational drug(s) / intervention(s)

No additional intervention administered in this long term follow-up study

No additional intervention administered in this long term follow-up study: Safety follow-up for A2 Bio GT products administered in a previous interventional study

Study summary

This protocol is to ensure consistent long-term follow-up for delayed safety events in participants who received A2 Bio gene therapy (GT) products.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Received any amount of A2 Bio GT product on a previous A2 Bio interventional study 2. Able to provide written informed consent for this long-term follow-up study 3. Able to comply with study requirements Exclusion Criteria: 1\. There are no specific exclusion criteria for this study

Primary outcome measure(s)

Long-term safety of previous A2 Bio GT treatment — 15 years post treatment with A2 Bio GT product
Long-term safety of previous A2 Bio GT treatment as determined by incidence of adverse events (AEs)

Trial sites (3)

Facility	City	Region
Banner Health	Gilbert	Arizona
Mayo Clinic	Rochester	Minnesota
NYU Langone Medical Center	New York	New York

More A2 Biotherapeutics Inc. trials in the USA

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing Recruiting

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression Recruiting

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression Recruiting

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression Active, not recruiting

Other trials for the same condition

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) Recruiting

Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors Active, not recruiting

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer Recruiting

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06885424 on ClinicalTrials.gov ↗ ← All trials in the USA